TKPHF (Takeda Pharmaceutical Co) Retained Earnings: $4,149 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TKPHF Takeda Pharmaceutical Co Ltd TKPHF
77 GF Score
Price $35.89
GF Value $29.62
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Retained Earnings?

Takeda Pharmaceutical Co TKPHF +2.72% 77 Retained Earnings is $4,149 Mil as of Jun. 2026. GuruFocus rates TKPHF with a GF Score™ of 77/100 and a GF Value™ of $29.62 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Takeda Pharmaceutical Co's retained earnings for the quarter that ended in Jun. 2026 was $4,149 Mil.

Takeda Pharmaceutical Co's quarterly retained earnings declined from Dec. 2025 ($7,027 Mil) to Mar. 2026 ($4,489 Mil) and declined from Mar. 2026 ($4,489 Mil) to Jun. 2026 ($4,149 Mil).

Takeda Pharmaceutical Co's annual retained earnings declined from Mar. 2024 ($9,286 Mil) to Mar. 2025 ($7,967 Mil) and declined from Mar. 2025 ($7,967 Mil) to Mar. 2026 ($4,489 Mil).


Takeda Pharmaceutical Co  (OTCPK:TKPHF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Takeda Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Retained Earnings Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,478.90 11,529.98 9,285.92 7,967.30 4,489.34

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,005.70 7,768.40 7,027.30 4,489.34 4,148.83
TKPHF
77GF Score
Takeda Pharmaceutical Co Ltd TKPHF
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $4,149 Mil mean?
Takeda Pharmaceutical Co (TKPHF) has a Retained Earnings of $4,149 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Retained Earnings too high?
Takeda Pharmaceutical Co's current Retained Earnings is $4,149 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Retained Earnings compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Retained Earnings of $4,149 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Retained Earnings is $4,149 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TKPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $29.62, compared to a current price of $35.89 — trading 21.2% above its estimated fair value. The current Retained Earnings is $4,149 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TKPHF), the current Retained Earnings is $4,149 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TKPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $35.89 is trading 21.2% above its estimated GF Value™ of $29.62. GuruFocus considers Takeda Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for TKPHF:

  • Retained Earnings: $4,149 Mil
  • GF Value™: $29.62 vs. price of $35.89 (21.2% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the TKPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
77GF Score

Get the complete analysis for TKPHF

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.89
Price
$29.62
GF Value